Thrombotic disorders

Gresele P, Page C, Fuster V et al (2002) Platelets in thrombotic and non-thrombotic disorders. Cambridge University Press, New York... 

Fareed J., Bick R. L., Hoppensteadt D. A., Bermes E. W. Molecular markers of hemostatic activation Applications in the diagnosis of thrombosis and vascular and thrombotic disorders. Clin Appl Thromb Haemost 1995 1, 87-102. 

Fischer, K. 2004. The role of recombinant hirudins in the management of thrombotic disorders. Biodrugs 18(4), 235-268. 

Dysregulation of the vascular endothelium has emerged as a critical component of most thrombotic disorders [10, 21]. Often without any anatomical sign of atherosclerosis, many cardiovascular diseases express a vasomotor abnormality termed endothelial dysfunction, indexed clinically as impaired endothelium-dependent vasodilation [31]. Although its mechanism is multifactorial, endothelial dysfunction is characterized by diminished vascular NO production and/or bioavailability [32]. The... 

Thrombotic disorders Thrombotic disorders (thrombophlebitis, cerebrovascular disorders, retinal thrombosis, pulmonary embolism) occasionally occur in patients taking progestins. 

Thromboembolism Be alert to the earliest symptoms of thromboembolic and thrombotic disorders. Should any of these occur or be suspected, discontinue the drug immediately. 

Thromboembolic disorders Be alert to the earliest manifestations of thrombotic disorders. If any of these occur or are suspected, do not readminister the drug. Ocular disorders Do not readminister pending examination if there is a sudden partial or complete loss of vision or if there is a sudden onset of proptosis, diplopia, or migraine. If examination reveals papilledema or retinal vascular lesions, do not readminister. 

Signs and symptoms of thromboembolic or thrombotic disorders, including loss of coordinaf ion, numbness or weakness of an exf remify, shortness of breath, speech or vision disturbance, sudden severe headache, and pain in the chest, leg, or groin... 

Contraindications Carcinoma of breast estrogen-dependent neoplasm history of or active thrombotic disorders, such as cerebral apoplexy, thrombophlebitis, or thromboembolic disorders hypersensitivity to progestins severe hepatic dysfunction undiagnosed abnormal genital bleeding... 

The thrombotic disorders include atherothrombosis, endothelial dysfunction, hypercoagulable states, and the thrombophilias. Atherothrombosis or atherosclerosis is a systemic disease of the vessel wall occuring in the aorta, carotid, coronary, and peripheral arteries. The associated inflammatory response is mediated by macrophages and T-lymphocytes with continued smooth muscle cell proliferation, The levels of endothelin-l (ET-I), an extremely potent... 

Twenty-five percent ofthrombophilic patients develop thrombosis at unusual sites resulting in cerebral venous thrombosis, mesenteric vein thrombosis, hepatic venous thrombosis, retinal vein thrombosis, purpura fulminans, splenic vein thrombosis, portal vein thrombosis, renal vein thrombosis, or axillary vein thrombosis. The thrombotic disorders may involve inflammatory factors that contribute to the vascular deficit. In addition, embolic events also play a role in the development of these thrombotic complications. 

I 14 Kane WH, Davie EW. Blood coagulation factors V and VIII structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders. Blood 1988 71 539-555. 

In one report, an array of antigens patterned on a substrate was constructed for detection of IgG antibodies from various species. This method, termed miniaturized mosaic immunoassay, is rendered possible by using the PDMS channel for patterning materials [1027]. In another report, various antibodies were patterned via the PDMS channel on a substrate for detection of three antigens FI antigen (from Yersinia pestis), staphylococcal enterotoxin B, and D-dimer (DDi, a marker of sepsis and thrombotic disorder) [1028],... 

Ticlopidine (136), a thienopyridine derivative, and related compounds such as the ester (137) are being tested for use in the chronic therapy of arterial thrombotic disorders <92MI 706-01). 

Each setting in the design of an animal model can answer specific question in relation to certain thrombotic disorders in human. However, the ultimate model of human thrombosis is in humans. 

In earlier, (I), and subsequent investigations, (II), by the authors (1,2), respectively, additional pyrimidinone derivatives were prepared, which were effective as serine protease inhibitors, and used in the treatment of thrombotic disorders. 

Benzo-heterobicycles, (IV), prepared by Wade (5), (V), and Pinto (6), (VI), respectively, were effective as inhibitors of trypsin-based serine proteases, especially factor Xa, and used in in the treatment of thrombotic disorders. 

Utility Treatment Platelet-mediated Thrombotic Disorders... 

PAR-1, results in the formation of platelet aggregation causing thrombotic disorders such as myocardial infarction, stroke, angina, and atherosclerosis. Benzimidazolone peptidomimetic derivatives effective as thrombin receptor antagonists have been prepared to address this disorder. 

Indazole and indole urea-peptoid derivatives, (V), prepared by McComsey (6) were effective as PAR-1 antagonists and used to mediate platelet thrombotic disorders. 

Hofmeister (5) prepared 4-phenyltetrahydroisoquinolinium derivatives, (HI), for the treatment of left-ventricular hypertrophy and related thrombotic disorders. 

---